CORRECTED-Gossamer Bio Q4 net loss widens

Overview

• US biopharma developer's Q4 revenue increased yr/yr, net loss widened to $47.2 mln

• Company implemented reduction in force to align resources with near-term priorities

Outlook

• Company expects current cash to fund operations into Q1 2027

Result Drivers

• PROSERA TRIAL OUTCOME - Company said Q4 results and near-term focus were shaped by the Phase 3 PROSERA trial, which did not meet its primary endpoint and prompted further data analysis and regulatory engagement

• Cash, cash equivalents and marketable securities as of December 31, 2025, were $136.9 million

• COST CONTAINMENT - Company implemented a reduction in force and other cost-containment measures to align resources with near-term priorities

Company press release: ID:nBw6N1yfFa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Gossamer Bio Inc is $2.00, about 338.6% above its March 16 closing price of $0.46

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.